Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.

Volume: 125, Issue: 9, Pages: 855 - 867
Published: Oct 11, 2019
Abstract
Given that cardiovascular safety concerns remain the leading cause of drug attrition at the preclinical drug development stage, the National Center for Toxicological Research of the US Food and Drug Administration hosted a workshop to discuss current gaps and challenges in translating preclinical cardiovascular safety data to humans. This white paper summarizes the topics presented by speakers from academia, industry, and government intended to...
Paper Details
Title
Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.
Published Date
Oct 11, 2019
Volume
125
Issue
9
Pages
855 - 867
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.